CXCR4 polymorphism predicts progression-free survival in metastatic colorectal cancer patients treated with first-line bevacizumab-based chemotherapy.
Matsusaka S, Cao S, Hanna DL, Sunakawa Y, Ueno M, Mizunuma N, Zhang W, Yang D, Ning Y, Stintzing S, Sebio A, Stremitzer S, Yamauchi S, Parekh A, Okazaki S, Berger MD, El-Khoueiry R, Mendez A, Ichikawa W, Loupakis F, Lenz HJ.
Matsusaka S, et al. Among authors: ichikawa w.
Pharmacogenomics J. 2017 Dec;17(6):543-550. doi: 10.1038/tpj.2016.59. Epub 2016 Aug 9.
Pharmacogenomics J. 2017.
PMID: 27503580
Free PMC article.